Evidence map›Paper›PMID 27649498›Full record

ArticlePloS one2016

High Throughput Random Mutagenesis and Single Molecule Real Time Sequencing of the Muscle Nicotinic Acetylcholine Receptor.

Paul J Groot-Kormelink, Sandrine Ferrand, Nicholas Kelley, Anke Bill, Felix Freuler, Pierre-Eloi Imbert, Anthony Marelli, Nicole Gerwin, Lucia G Sivilotti, Loren Miraglia and 4 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 3 countries.

Paul J Groot-KormelinkMusculoskeletal Disease Area, Novartis Institutes for BioMedical Research, Basel, Switzerland.
Sandrine FerrandCenter for Proteomic Chemistry, Novartis Institutes for BioMedical Research, Basel, Switzerland.
Nicholas KelleyAnalytical Sciences and Imaging, Novartis Institutes for BioMedical Research, Basel, Switzerland.
Anke BillCenter for Proteomic Chemistry, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, United States of America.
Felix FreulerCenter for Proteomic Chemistry, Novartis Institutes for BioMedical Research, Basel, Switzerland.
Pierre-Eloi ImbertCenter for Proteomic Chemistry, Novartis Institutes for BioMedical Research, Basel, Switzerland.
Anthony MarelliGenomics Institute of the Novartis Research Foundation, Novartis Institutes for BioMedical Research, San Diego, California, United States of America.
Nicole GerwinMusculoskeletal Disease Area, Novartis Institutes for BioMedical Research, Basel, Switzerland.
Lucia G SivilottiDepartment of Neuroscience, Physiology and Pharmacology, University College London, London, United Kingdom.
Loren MiragliaGenomics Institute of the Novartis Research Foundation, Novartis Institutes for BioMedical Research, San Diego, California, United States of America.
Anthony P OrthGenomics Institute of the Novartis Research Foundation, Novartis Institutes for BioMedical Research, San Diego, California, United States of America.
Edward J OakeleyAnalytical Sciences and Imaging, Novartis Institutes for BioMedical Research, Basel, Switzerland.
Ulrich SchopferCenter for Proteomic Chemistry, Novartis Institutes for BioMedical Research, Basel, Switzerland.
Sandra SiehlerCenter for Proteomic Chemistry, Novartis Institutes for BioMedical Research, Basel, Switzerland.
Novartis (Switzerland) · CHGenomics Institute of the Novartis Research Foundation · USNovartis Institutes for BioMedical ResearchUniversity College London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High throughput random mutagenesis is a powerful tool to identify which residues are important for the function of a protein, and gain insight into its structure-function relation. The human muscle nicotinic acetylcholine receptor was used to test whether this technique previously used for monomeric receptors can be applied to a pentameric ligand-gated ion channel. A mutant library for the α1 subunit of the channel was generated by error-prone PCR, and full length sequences of all 2816 mutants were retrieved using single molecule real time sequencing. Each α1 mutant was co-transfected with wildtype β1, δ, and ε subunits, and the channel function characterized by an ion flux assay. To test whether the strategy could map the structure-function relation of this receptor, we attempted to identify mutations that conferred resistance to competitive antagonists. Mutant hits were defined as receptors that responded to the nicotinic agonist epibatidine, but were not inhibited by either α-bungarotoxin or tubocurarine. Eight α1 subunit mutant hits were identified, six of which contained mutations at position Y233 or V275 in the transmembrane domain. Three single point mutations (Y233N, Y233H, and V275M) were studied further, and found to enhance the potencies of five channel agonists tested. This suggests that the mutations made the channel resistant to the antagonists, not by impairing antagonist binding, but rather by producing a gain-of-function phenotype, e.g. increased agonist sensitivity. Our data show that random high throughput mutagenesis is applicable to multimeric proteins to discover novel functional mutants, and outlines the benefits of using single molecule real time sequencing with regards to quality control of the mutant library as well as downstream mutant data interpretation.

Indexed as

MutagenesisAmino Acid SequenceBridged Bicyclo Compounds, HeterocyclicBungarotoxinsCalciumHEK293 CellsHigh-Throughput Nucleotide SequencingHumansIon TransportMusclesMutationNicotinic AgonistsNicotinic AntagonistsPyridinesReceptors, NicotinicSequence Homology, Amino AcidBridged Bicyclo Compounds, HeterocyclicBungarotoxinsCalciumCHRNA1 protein, humanepibatidineNicotinic AgonistsNicotinic AntagonistsPyridinesReceptors, NicotinicTubocurarine

Identifiers

PMID27649498
PMCPMC5029940
OpenAlexW2521414930

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.